Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 20 Jun 2017 Planned End Date changed from 1 Sep 2019 to 1 Sep 2018.
- 10 Jun 2017 Biomarkers information updated
- 11 Jul 2016 Status changed from recruiting to active, no longer recruiting.